Human Anti-SHH Recombinant Antibody (clone 6D7) (CAT#: NS-082CN)

Figure 1 Differential binding of human anti-hedgehog antibodies to recombinant human hedgehog proteins.

mAbs 6D7 (A) and 3H8 (B) were serially diluted and binding to recombinant human SHH C24II, IHH C28II, and DHH C23II was detected after 16 hours of incubation.

Michaud, N. R., Wang, Y., McEachern, K. A., Jordan, J. J., Mazzola, A. M., Hernandez, A.,... & Wang, L. (2014). Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Molecular cancer therapeutics, 13(2), 386-398.

Figure 2 Neutralizing activity of anti-hedgehog mAbs in cellular assays.

A and B, hedgehog antibodies inhibit the mGLI1 luciferase reporter expressed in NIH3T3 cells. Varying concentrations of 6D7, 3H8, 5E1, or negative control mAb R347 were mixed with 1 mg/ml (A) hSHH C24II or (B) human/mouse IHH C28II and incubated with cells for 24 hours. Values plotted are percentage of ligand stimulation in the absence of antibody and they represent mean ± SEM. C and D, hedgehog antibodies inhibit osteoblast differentiation of C3H10T1/2 cells induced by hedgehog ligands. C3H10T1/2 cells were treated with 600 ng/ml SHH C24II (C) or 3 mg/ml IHH C28II (D) for 3 days in the presence of serially diluted antibody. Osteoblast differentiation was measured by alkaline phosphatase (Alk Phos) activity. Values are mean ± SEM. E and F, hedgehog antibodies inhibit induction of endogenous mGLI1 by hedgehog proteins.

Michaud, N. R., Wang, Y., McEachern, K. A., Jordan, J. J., Mazzola, A. M., Hernandez, A.,... & Wang, L. (2014). Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Molecular cancer therapeutics, 13(2), 386-398.

Figure 3 The results from pharmacodynamic modulation of mouse GIi 1 and Ptcl in the stroma of Colo205 Xenograft tumors by particular antibodies.